Previous 10 | Next 10 |
Minerva Neurosciences tanks ( NERV -81.4% ) after the company announces disappointing results from Phase 3 clinical trial evaluating roluperidone (MIN-101) in adults with negative symptoms of schizophrenia More news on: Minerva Neurosciences, Inc., Healthcare stocks news, Stocks on t...
The 64 mg and 32 mg doses were not statistically significantly different from placebo at Week 12 on the primary endpoint, the PANSS Marder Negative Symptoms Factor Score (p ≤0.064 and 0.259, respectively), or the key secondary endpoint, the Personal and Social Performance Scale Tot...
Image source: The Motley Fool. Minerva Neurosciences Inc (NASDAQ: NERV) Q1 2020 Earnings Call May 4, 2020 , 8:30 a.m. ET Operator Continue reading
Minerva Neurosciences, Inc. (NERV) Q1 2020 Earnings Conference Call May 04, 2020 08:30 AM ET Company Participants William Boni - Vice President of Investor Relations & Corporate Communications Remy Luthringer - Executive Chairman & Chief Executive Officer Rick Russell - P...
Minerva Neurosciences (NASDAQ: NERV ): Q1 GAAP EPS of -$0.31 beats by $0.05 . More news on: Minerva Neurosciences, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
WALTHAM, Mass., May 04, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the ...
WALTHAM, Mass., April 27, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results and busin...
WALTHAM, Mass., March 24, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies addressing high unmet medical needs in the treatment of central nervous system (CNS) disorders, today announced t...
WALTHAM, Mass., March 12, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat unmet medical needs of central nervous system (CNS) disorders, wishes to address a sharp redu...
Image source: The Motley Fool. Minerva Neurosciences Inc (NASDAQ: NERV) Q4 2019 Earnings Call Mar 9, 2020 , 8:30 a.m. ET Operator Continue reading
News, Short Squeeze, Breakout and More Instantly...
Minerva Neurosciences Inc Company Name:
NERV Stock Symbol:
NASDAQ Market:
Minerva Neurosciences Inc Website:
BURLINGTON, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported business updates and financial results for the first q...
A look at the top 10 most actives in the United States SoundHound AI Inc. (SOUN) rose 19.3% to $6.86 on volume of 301,330,136 shares Canoo Inc. (GOEV) rose 8.3% to $0.1138 on volume of 118,801,751 shares Ault Alliance Inc. (AULT) rose 19.1% to $0.4642 on volume of 117,184,555 shares Mar...